Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $7.13, up 0.56% on the session, giving a market capitalisation of $388.0M. On trailing twelve-month figures it carries a trailing P/E of -2.46, a net margin of -4955.7%. Its beta of 1.27 implies it has historically moved more than the broad market.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Upstream Bio, Inc. is most often compared with the following Healthcare names: